Schellenberg Wittmer advises Swisscanto as lead investor on Piomic Medical's USD 25 million financing

29.09.2026

Schellenberg Wittmer advised Swisscanto as lead investor on Piomic Medical's USD 25 million financing.

Show more

 

Schellenberg Wittmer advised Quorum Cyber in its acquisition of Ontinue

28.09.2026

Schellenberg Wittmer advised Quorum Cyber, a leading Microsoft-focused cybersecurity services provider, in its acquisition of Zurich-based Ontinue, a managed extended detection and response (MXDR) provider.

Show more

 

Schellenberg Wittmer advises MV Invest AG with its FINMA license

24.09.2026

Schellenberg Wittmer advised MV Invest AG in obtaining its FINMA license as asset manager of collective assets with the Swiss Financial Supervisory Authority (FINMA).

Show more

 

Schellenberg Wittmer advises Marubeni Corporation on its acquisition of TOLUS Group AG

01.09.2026

Schellenberg Wittmer acted as Swiss counsel for Marubeni Corporation on the acquisition of Swiss TOLUS Group AG.

Show more

 

Schellenberg Wittmer advised Boehringer Ingelheim on its acquisition of Evax AG

25.08.2026

Schellenberg Wittmer advised Boehringer Ingelheim, one of the largest pharmaceutical companies, on the acquisition of Evax AG. Evax AG is a Swiss biotech company focused on equine health.

Show more